TCIM
BMRN icon

TIAA CREF Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

TIAA CREF Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$181M Buy
2,040,932
+555,842
+37% +$51.5M 0.13% 162
2018
Q4 		$126M Buy
1,485,090
+165,646
+13% +$15.8M 0.1% 195
2018
Q3 		$128M Buy
1,319,444
+255,291
+24% +$25.5M 0.08% 226
2018
Q2 		$100M Sell
1,064,153
-349,191
-25% -$30.6M 0.07% 270
2018
Q1 		$115M Sell
1,413,344
-323,342
-19% -$27.7M 0.08% 255
2017
Q4 		$155M Sell
1,736,686
-410,022
-19% -$35.7M 0.1% 206
2017
Q3 		$200M Sell
2,146,708
-104,303
-5% -$9.22M 0.14% 153
2017
Q2 		$204M Buy
2,251,011
+875,686
+64% +$79.7M 0.14% 157
2017
Q1 		$121M Buy
1,375,325
+151,663
+12% +$13.5M 0.09% 251
2016
Q4 		$101M Sell
1,223,662
-163,529
-12% -$14.1M 0.08% 268
2016
Q3 		$128K Sell
1,387,191
-8,625
-0.6% -$812K 0.08% 240
2016
Q2 		$109M Sell
1,395,816
-149,568
-10% -$12.7M 0.08% 249
2016
Q1 		$127M Sell
1,545,384
-48,385
-3% -$3.94M 0.1% 210
2015
Q4 		$167M Buy
1,593,769
+111,026
+7% +$11.6M 0.13% 173
2015
Q3 		$156M Sell
1,482,743
-542,067
-27% -$72.4M 0.12% 179
2015
Q2 		$277M Sell
2,024,810
-222,273
-10% -$27.5M 0.2% 101
2015
Q1 		$280M Buy
2,247,083
+145,634
+7% +$15.4M 0.2% 115
2014
Q4 		$190M Buy
2,101,449
+1,247,649
+146% +$104M 0.13% 174
2014
Q3 		$61.6M Buy
853,800
+176,792
+26% +$11.6M 0.04% 427
2014
Q2 		$42.1M Buy
677,008
+185,815
+38% +$11.2M 0.03% 529
2014
Q1 		$33.5M Buy
491,193
+185,728
+61% +$13.7M 0.02% 610
2013
Q4 		$21.5M Sell
305,465
-63,203
-17% -$4.29M 0.02% 759
2013
Q3 		$26.6M Sell
368,668
-190,288
-34% -$12.6M 0.02% 655
2013
Q2 		$31.2M Buy
+558,956
New +$34.8M 0.03% 581

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TIAA CREF Investment Management's BMRN Position: Q1 2019 in Review

TIAA CREF Investment Management increased its BioMarin Pharmaceuticals (BMRN) stake by 37% in Q1 2019, buying an estimated $51.5M and bringing the position to 2,040,932 shares worth $181M. The position accounts for 0.13% of the portfolio, ranked #162.

TIAA CREF Investment Management first reported a position in BMRN in Q2 2013 and has held it in 24 quarters since. The position peaked at $280M in Q1 2015. 485 funds tracked by Wall St. Rank hold BMRN as of Q1 2019.

  • TIAA CREF Investment Management held 2,040,932 shares of BioMarin Pharmaceuticals worth $181M as of Q1 2019.
  • TIAA CREF Investment Management bought 555,842 BioMarin Pharmaceuticals shares in Q1 2019, an estimated $51.5M.
  • BioMarin Pharmaceuticals made up 0.13% of TIAA CREF Investment Management's portfolio in Q1 2019, its #162 holding.
  • TIAA CREF Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's BioMarin Pharmaceuticals position peaked at $280M in Q1 2015.
  • 485 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.